Ergomed plc Notice of Interim Results (7548A)
14 September 2018 - 4:01PM
UK Regulatory
TIDMERGO
RNS Number : 7548A
Ergomed plc
14 September 2018
PRESS RELEASE
FOR IMMEDIATE RELEASE
Notice of Interim Results
London, UK - 14 September 2018: Ergomed plc (LSE: ERGO)
('Ergomed' or the 'Company'), a company focused on providing
specialised services to the pharmaceutical industry, will announce
its interim results for the six months ended 30 June 2018 on
Wednesday 19(th) September 2018.
Stephen Stamp, Chief Executive Officer and Stuart Jackson, Chief
Financial Officer, will host a presentation and conference call for
analysts at 8:30am BST on the day of the results at the offices of
Numis Securities, The London Stock Exchange Building, 10
Paternoster Square, London, EC4M 7LT.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 503 205
Stephen Stamp (Chief Executive Officer)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black (Joint Broker)
Consilium Strategic Communications - Tel: +44 (0) 20 3709 5700
for UK enquiries
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services offering encompasses a complete suite of
specialist pharmacovigilance solutions, integrated under the
PrimeVigilance brand, in addition to a full range of high quality
contract research and trial management services (CRO). Leveraging
its CRO expertise, Ergomed also has a drug development portfolio of
co-development partnerships and wholly-owned programmes. For
further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORDBGDCUBBBGIX
(END) Dow Jones Newswires
September 14, 2018 02:01 ET (06:01 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024